BR112016019534A2 - métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor - Google Patents
métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumorInfo
- Publication number
- BR112016019534A2 BR112016019534A2 BR112016019534A BR112016019534A BR112016019534A2 BR 112016019534 A2 BR112016019534 A2 BR 112016019534A2 BR 112016019534 A BR112016019534 A BR 112016019534A BR 112016019534 A BR112016019534 A BR 112016019534A BR 112016019534 A2 BR112016019534 A2 BR 112016019534A2
- Authority
- BR
- Brazil
- Prior art keywords
- tumor growth
- methods
- immune response
- response against
- eliciting
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000004614 tumor growth Effects 0.000 title 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US201462076411P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016019534A2 true BR112016019534A2 (pt) | 2017-10-24 |
Family
ID=54009773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016019534A BR112016019534A2 (pt) | 2014-02-25 | 2015-02-25 | métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor |
Country Status (12)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| AU2012229218B2 (en) | 2011-03-11 | 2017-03-02 | Advaxis, Inc. | Listeria-based adjuvants |
| WO2013138337A1 (en) | 2012-03-12 | 2013-09-19 | Advaxis | Suppressor cell function inhibition following listeria vaccine treatment |
| SG11201606677XA (en) | 2014-02-18 | 2016-09-29 | Advaxis Inc | Biomarker directed multi-target immunotherapy |
| MX2016011537A (es) * | 2014-03-05 | 2017-05-01 | Advaxis Inc | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. |
| AU2015250111A1 (en) | 2014-04-24 | 2016-12-08 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| AU2017367642A1 (en) | 2016-11-30 | 2019-05-30 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| KR102794940B1 (ko) | 2017-09-19 | 2025-04-14 | 어드박시스, 인크. | 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법 |
| CN118888004A (zh) | 2017-10-10 | 2024-11-01 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en active Application Filing
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240038103A (ko) | 2024-03-22 |
| SG11201607036XA (en) | 2016-09-29 |
| NZ723750A (en) | 2024-02-23 |
| CN106661538A (zh) | 2017-05-10 |
| JP2017507943A (ja) | 2017-03-23 |
| MX2016011114A (es) | 2017-02-20 |
| EP3110942A4 (en) | 2017-08-30 |
| AU2015223136A1 (en) | 2016-09-22 |
| KR20160122829A (ko) | 2016-10-24 |
| WO2015130810A3 (en) | 2016-01-28 |
| IL247436A0 (en) | 2016-11-30 |
| RU2016137834A (ru) | 2018-03-29 |
| CA2940646A1 (en) | 2015-09-03 |
| EP3110942A2 (en) | 2017-01-04 |
| WO2015130810A2 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016019534A2 (pt) | métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor | |
| CY1122602T1 (el) | Αντιμετωπιση των nafld και nash | |
| IL263382A (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
| BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
| IL268704B (en) | Formulations of human anti-rankl antibodies, and methods of using the same | |
| SV2018005659A (es) | Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| IL252159B (en) | Methods and formulations for the treatment of diseases of the blood vessels of the eye | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| BR112016026378A2 (pt) | formulações e métodos para tratamento com queratina | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| BR112017008959A2 (pt) | método para tratamento de uma doença. | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| MX383484B (es) | Método para tratar el cáncer. | |
| MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
| BR112016028910A2 (pt) | sistema e método para ancoragem de válvula cardíaca | |
| MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| BR112017019025A2 (pt) | aplicadores de implante e métodos para administrar implantes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |